AIIMS Ethics Committee approved starting human clinical trials of the indigenously developed Covid-19 vaccine candidate, Covaxin. Covaxin has been developed by the Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The trials will begin from Monday, July 20.
Healthy participants between 18 to 55 years of age, with no comorbidities and without a history of Covid-19, will be selected for the test. The enrollment process will start from Monday. In the first and second phases, AIIMS-Delhi will choose only 100 participants out of 375 volunteers and the remaining will participate at other sites.
To participate, send an email at Ctaiims.covid19@gmail.com or send an SMS or call on 7428847499.
It may be noted that there are 12 places where the trial for Covaxin is taking place as per the Indian Council for Medical Research (ICMR).
Director General of Indian Council of Medical Research (ICMR) Dr Balram Bhargava informed that there are two Indian indigenous candidate vaccines and both have gone successful toxicity studies in rats, mice and rabbits. The data was submitted to the Drugs Controller General of India (DCGI) following which both these candidate vaccines got clearance to start the early phase of human trials he had said.
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 20 2020 | 9:11 AM IST